![Moses Chen](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Moses Chen
Direttore/Membro del Consiglio presso
APOLLOMICS, INC.
Patrimonio netto: 51 223 $ in data 31/05/2026
Profilo
Hong-Jung Chen is currently Chairman & Chief Executive Officer at Maxpro Co., Ltd. since 2018.
Dr. Chen is also an Independent Director at Apollomics, Inc. and Apollomics, Inc. (United States) since 2023.
Former positions include Chairman & Chief Executive Officer at Maxpro Capital Acquisition Corp.
from 2021 to 2023, Managing Director at Maxpro Ventures Ltd. from 2018 to 2024, and Chief Operations Officer & Vice President at SyneuRx International (Taiwan) Corp.
from 2014 to 2017.
Education includes doctorate degrees from the University of Medicine & Dentistry of New Jersey and Rutgers State University of New Jersey.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
| 15/06/2026 | 3.620 ( 0,16% ) | 51 223 $ | 31/05/2026 |
Posizioni attive di Moses Chen
| Società | Posizione | Inizio |
|---|---|---|
| APOLLOMICS, INC. | Direttore/Membro del Consiglio | 30/03/2023 |
Maxpro Co., Ltd.
 Maxpro Co., Ltd. Financial ConglomeratesFinance Provides financial services and programming, scripts, indicators and automated-trading systems | Amministratore Delegato | 01/05/2018 |
Apollomics, Inc. (United States)
 Apollomics, Inc. (United States) BiotechnologyHealth Technology Develops mono therapies and combination therapies of tumor-targeting and immuno-oncology agents | Direttore/Membro del Consiglio | 30/03/2023 |
Precedenti posizioni note di Moses Chen
| Società | Posizione | Fine |
|---|---|---|
Maxpro Ventures Ltd.
 Maxpro Ventures Ltd. Investment ManagersFinance Maxpro Ventures invests in companies located across the globe. The firm targets companies operating in the fields of biotechnology, pharmaceuticals, business development and finance sectors. It provides financing for early and later stage capital requirements. | Corporate Officer/Principal | 01/02/2024 |
| MAXO CAP | Amministratore Delegato | 01/03/2023 |
| SYNEURX INTERNATIONAL (TAIWAN) CORP. | Direttore operativo | 01/01/2017 |
Formazione di Moses Chen
Esperienze
Posizioni ricoperte
Attive
Inattive
Società nel listino
Aziende private
Relazioni
6
Relazioni di 1° grado
8
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 8 |
|---|---|
University of Medicine & Dentistry of New Jersey
 University of Medicine & Dentistry of New Jersey Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Rutgers State University of New Jersey
 Rutgers State University of New Jersey Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
SyneuRx International (Taiwan) Corp.
 SyneuRx International (Taiwan) Corp. BiotechnologyHealth Technology Researches and develops drugs to treat central nervous system disorders | Health Technology |
Apollomics, Inc. (United States)
Apollomics, Inc. (United States) BiotechnologyHealth Technology Develops mono therapies and combination therapies of tumor-targeting and immuno-oncology agents | Health Technology |
Maxpro Co., Ltd.
Maxpro Co., Ltd. Financial ConglomeratesFinance Provides financial services and programming, scripts, indicators and automated-trading systems | Finance |
Maxpro Capital Acquisition Corp.
 Maxpro Capital Acquisition Corp. Financial ConglomeratesFinance Operates as a blank check company | Finance |
Maxpro Ventures Ltd.
Maxpro Ventures Ltd. Investment ManagersFinance Maxpro Ventures invests in companies located across the globe. The firm targets companies operating in the fields of biotechnology, pharmaceuticals, business development and finance sectors. It provides financing for early and later stage capital requirements. | Finance |
Apollomics, Inc.
 Apollomics, Inc. Financial ConglomeratesFinance Operates as a biotechnology company that focuses on development of novel medicines for cancer patients | Finance |
